1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
HLB Co., Ltd.

HLB Co., Ltd.

028300.KQ
HLB Co., Ltd.KR flagKOSDAQ
36,600.00
KRW
-15,600.00
- -
4.86TMarket Cap
HLB Co., Ltd.
028300.KQ
(KOSDAQ)

Recent

price

36,600.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
992.3
1,512.61
1,012.67
337.53
561.44
457.51
333.1
251.78
379.06
333.16
238.14
580.72
1,471.53
353.87
521.42
641.31
646.67
Revenue per Share
-569.71
-166.91
-144.87
-138.61
-44.25
150.36
-146.05
-180.9
265.47
-384.9
-339.52
-816.08
-640
-1,547
-704
-1,680
-1,474.7
Basic EPS, GAAP
-121.21
-117.49
-59.32
-86.77
-91.78
-33.84
-138.95
-231.44
-312.61
-438.24
-557.41
-506.54
-609.57
-979.03
-1,082.1
-839.02
-747.98
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.35
- -
- -
- -
- -
- -
- -
Dividend per Share
-2,070.25
-2,143.7
-2,016.73
203.4
169.93
321.78
161.5
-17.85
620.18
140.07
-249.93
-1,078.81
-608.94
515.16
2,124.92
527.94
239.01
Book Value per Share
471.27
400.13
317.21
242.67
336.32
-193.64
-76.79
-141.7
795.31
482.86
1,244.5
1,435.83
2,900.32
2,895.08
2,599.86
1,224.88
1,105.66
Tangible Book Value per Share
44
46
51
62
66
84
90
91
95
115
236
120
122
121
131
131
132
Basic Weighted Avg Shares
43,732
69,518
51,642
20,808
37,186
38,461
30,139
23,007
36,186
38,421
56,177
69,826
179,708
42,901
68,126
84,173
85,198
Sales/Revenue/Turnover
-13.74
3.71
-5.65
-25.71
0.97
-15.5
-69.69
-113.51
-81.01
-125.65
-109.14
-142.95
-41.55
-270.29
-173.75
-117.16
-109.22
Operating Margin (%)
5,983
2,009
2,848
2,259
1,824
1,754
1,600
1,627
1,369
2,175
10,490
12,038
16,326
9,683
6,228
5,358
5,745
Depreciation Expense
-25,108
-7,671
-7,388
-8,545
-2,931
12,640
-13,215
-16,530
25,343
-44,386
-80,093
-98,125
-78,159
-187,547
-91,980
-220,501
-194,289
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-57.41
-11.03
-14.31
-41.07
-7.88
32.86
-43.85
-71.85
70.04
-115.53
-142.57
-140.53
-43.49
-437.17
-135.02
-261.96
-228.05
Profit Margin (%)
533
-1,406
-3,148
719
12,156
5,461
11,688
-7,009
96,209
1,980
153,546
66,322
143,245
58,074
11,563
-223,385
-252,752
Working Capital
7,444
3,304
2,768
1,797
8,405
5,374
6,056
4,320
31,555
75,451
9,346
57,111
13,682
31,794
58,788
74,652
67,463
LT Debt
23,306
21,191
21,586
15,502
23,020
114,390
124,073
113,679
209,524
189,242
557,429
512,185
698,978
615,312
652,114
494,414
493,871
Total Equity
- -
- -
- -
- -
- -
-6.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
31.36
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-24.63
65.99
-63.44
- -
- -
-117.8
- -
- -
- -
- -
-54.09
-127.12
-158.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
119,372
210,293
202,078
LT Borrowings
38,749
58,224
51,109
LT Finance Leases
12,703
16,428
16,353
Preferred Equity and Hybrid Capital
4
4
4
Shares Outstanding
131
133
133
Market Capitalization
4,976,767
6,661,917
6,666,477

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
120,655
124,277
95,894
Cash, Cash Equivalents & STI
47,996
87,776
56,667
Accounts Receivable, Net
9,415
9,520
9,977
Inventories
14,894
9,454
11,001
Total Current Liabilities
184,328
347,662
348,647
Payables & Accruals
- -
- -
- -
ST Debt
119,372
210,293
202,078
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.75%
-0.36%
-24.18%
Free Cash Flow
70.58%
5%
-22.11%
Net Income, GAAP
-39.66%
46.18%
139.73%
Sales/Revenue/Turnover
25.23%
37.58%
23.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,154
14,794
16,953
25,225
68,126
2025
17,664
15,732
22,111
28,665
84,173
2026
18,689
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
247
-795
31
- -
-704
2025
-490
-440
-557
- -
-1,680
2026
-286
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Quantum-Si incorporated (QSI)
BioGend Therapeutics Co., Ltd. (6733.TWO)
Heron Therapeutics, Inc. (0J4V.L)
hVIVO plc (HVO.L)
Graf Acquisition Corp. IV (GFOR-WT)
NetScientific plc (NSCI.L)
Business
HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber reinforced plastic (GRP) pipes in South Korea and internationally; engages in the repair, inspection, fabrication, and installation of lifeboats and pipes; develops and manufactures biopharmaceutical products such as anti-cancer drugs including Rivoceranib; produces and sells medical devices, quasi-drugs including alcohol swabs and sampling tools, in-vitro diagnostics using nanoparticles like graphene and carbon nanotubes, and femtech products such as feminine cleansers, wipes, pregnancy testers, ovulation testers, vaginitis test kits, and urethritis test kits; and participates in e-commerce, investment, and financing activities. Founded in 1975 and headquartered in Ulsan, South Korea, the company operates primarily in the biotechnology, healthcare, and marine composite materials sectors, serving shipbuilders, pharmaceutical markets, medical facilities, and consumer health customers across domestic and global markets. In September 2025, HLB Co., Ltd. agreed to acquire HLB Science Inc. from HLB Global Co., Ltd. and others for KRW 30.9 billion through a merger, involving issuance of 0.8 million common shares at a swap ratio of 0.044632 per HLB Science share to consolidate healthcare operations; additionally, in November 2025, HLB Group, which includes the company, hosted its first Pitch Day event under the HLB New Wave open innovation initiative to foster collaborations with promising bio firms in areas like funding, R&D, and commercialization.